

| | | | | | | | |
|--|----|---|------------|---|--|---|-------------------------------|
| Form PTO 1449 (Modified) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO. 284024US0PCT | | SERIAL NO. 10/566,101 | |
| LIST OF REFERENCES CITED BY APPLICANT | | | | APPLICANT Ramon MERCE VIDAL, et al. | | | |
| | | | | FILING DATE August 10, 2006 | | GROUP 1625 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| | AL | | | | | | |
| | AM | | | | | | |
| | AN | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES NO | | |
| | AO | WO 01/32646 A2 | 05/10/2001 | WIPO | | | |
| | AP | WO 02/066470 A1 | 08/29/2002 | WIPO | | | |
| | AQ | WO 95/32967 | 12/07/1995 | WIPO | | | |
| | AR | EP 0 733 628 A1 | 06/25/1996 | Europe | | | |
| | AS | | | | | | |
| | AT | | | | | | |
| | AU | | | | | | |
| | AV | | | | | | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | AW | D. HOYER, et al., Neuropharmacology, Vol. 36, No. 4/5, pp. 419-428 (1997) | | | | | |
| | AX | F.J. MONSMA, Jr., et al., Molecular Pharmacology, Vol. 43, pp. 320-327 (1993) | | | | | |
| | AY | M. RUAT, et al., Biochemical and Biophysical Research Communications, Vol. 193, No. 1, pp. 268-276 (1993) | | | | | |
| | AZ | R. KOHEN, et al., Journal of Neurochemistry, Vol. 66, No. 1, pp. 47-56 (1996) | | | | <input checked="" type="checkbox"/> Additional References sheet(s) attached | |
| Examiner | | | | | | | |
| *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--|-----|---|--|--|--|------------------------------|--|
| Form PTO 1449 (Modified) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO. 284024US0PCT | | SERIAL NO. 10/566,101 | |
| LIST OF REFERENCES CITED BY APPLICANT | | | | APPLICANT Ramon MERCE VIDAL, et al. | | | |
| | | | | FILING DATE August 10, 2006 | | GROUP 1625 | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | BAA | M. YOSHIOKA, et al., Ann. NY Acad. Sci. Vol. 861, pp. 244 (1998) | | | | | |
| | BAB | A.V. TURNBULL, et al., Diabetes, Vol. 51, pp. 2441-2449 (2002) | | | | | |
| | BAC | A. BOURSON, et al., British journal of Pharmacology, Vol. 125, pp. 1562-1566 (1998) | | | | | |
| | BAD | D.C. ROGERS, et al., Br. J. Pharmacol. Supp., Vol. 127, pp. 22P (1999) | | | | | |
| | BAE | A. BOURSON, et al., J. Pharmacol. Exp. Ther., Vol. 274, No. 1, pp. 173-180 (1995) | | | | | |
| | BAF | A.J. SLEIGHT, et al., Behavioural Brain Research, Vol. 73, pp. 245-248 (1996) | | | | | |
| | BAG | T.A. BRANCHEK, et al., Annu. Rev. Pharmacol. Toxicol, Vol. 40, pp. 319-334 (2000) | | | | | |
| | BAH | C. ROUTLEDGE, British Journal of Pharmacology, Vol 130, pp. 1606-1612 (2000) | | | | | |
| | BAI | B.L. ROTH, et al., J. Pharmacol. Exp. Ther., Vol. 268, pp. 1403-1410 (1994) | | | | | |
| | BAJ | C.E. GLATT, et al., Molecular Medicine, Vol. 1, No. 4, pp. 398-406 (1995) | | | | | |
| | BAK | T. SHINKAI, et al., American Journal of Medical Genetics (Neuropsychiatric Genetics), Vol. 88, pp. 120-122 (1999) | | | | | |
| | BAL | C. GERARD, et al., Brain Research, Vol. 746, pp. 207-219 (1997) | | | | | |
| | BAM | M.R. PRANZATELLI, Drugs of Today, Vol. 33, No. 6, pp. 379-392 (1997) | | | | | |
| | BAN | E.E. GILBERT, Synthesis-International Journal of Methods in Synthetic Organic Chemistry No. 1, pp. 3-10 (1969) | | | | | |
| | BAQ | L.D. BASANAGOUDAR, et al., J. Indian Chem. Soc., Vol. 49, No. 8, pp. 811-813 (1972) | | | | | |
| | BAP | S.A. YAMASHKIN, et al., Chemistry of Heterocyclic Compounds, Vol. 35, No. 12, pp. 1426-1432 (1999) | | | | | |
| | BAQ | S.R. BOOTHROYD, et al., Tetrahedron Letters, Vol. 36, No. 14, pp. 2411-2414 (1995) | | | | | |
| Examiner | | | | | | Date Considered | |
| *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--|-----|--|--|--|--|--------------------------|--|
| Form PTO 1449 (Modified) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO. 284024US0PCT | | SERIAL NO. 10/566,101 | |
| LIST OF REFERENCES CITED BY APPLICANT | | | | APPLICANT Ramon MERCE VIDAL, et al. | | | |
| | | | | FILING DATE August 10, 2006 | | GROUP 1625 | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | CAA | J.E. MACOR, et al., Synthetic Communications, Vol. 23, No. 1, pp. 65-72 (1993) | | | | | |
| | CAB | M. MACCHIA, et al., IL. Farmaco, Vol. 51, No. 1, pp. 75-78 (1996) | | | | | |
| | CAC | S.S. BHAGWAT, et al., Tetrahedron Letters, Vol. 35, No. 12, pp. 1847-1850 (1994) | | | | | |
| | CAD | L.D. BRATTON, et al., J. Heterocyclic Chem., vol. 37, pp. 1103-1108 (2000) | | | | | |
| | CAE | O. OTTONI, et al., Tetrahedron Letters, Vol. 40, pp. 1117-1120 (1999) | | | | | |
| | CAF | S.L. VOROBIEVA, et al., Khim Geterosiki Soedin (KGSSAQ) (5), pp. 636-637 (1991) | | | | | |
| | CAG | A.R. KATRITZKY, et al., Org. Prep. Proceed. Inc. (OPPIAK), Vol. 23, No. 3, pp. 357-363 (1991) | | | | | |
| | CAH | N. MOSKALEV, et al., Heterocycles (HTCYAM), Vol. 52, No. 2, pp. 533-536 (2000) | | | | | |
| | CAI | P.J. MUNSON, et al., Analytical Biochemistry, Vol. 107, pp. 220-239 (1980) | | | | | |
| | CAJ | A. KASK, et al., European Journal of Pharmacology, Vol. 414, pp. 215-224 (2001) | | | | | |
| | CAK | "Oral drug deliver, small intestine and colon", Encyclopedia of Controlled Drug Deliver, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York, Vol. 2, 698-728 (1999) | | | | | |
| | CAL | W.D. HIRST, et al., British Journal of Pharmacology, Vol. 130, pp. 1597-1605 (2000) | | | | | |
| | CAM | M.L. WOOLLEY, et al., Neuropharmacology, Vol. 41, pp. 210-219 (2001) | | | | | |
| | CAN | M. ABOU-GHARBIA, et al., Eur. J. Med. Chem., Vol. 23, pp. 373-377 (1988) | | | | | |
| | CAO | K. YAMADA, et al., Heterocycles, Vol. 55, No. 6, pp. 1151-1159 (2001) | | | | | |
| | CAP | K. TAKADA, et al., "Oral Drug Delivery", Encyclopedia of Controlled Drug Deliver, Mathiowiz, E., (ed.), John Wiley and Sons, Inc., New York, Vol. 2, pp. 728-742 (1999) | | | | | |
| | CAQ | Dictionary of Microbiology and Molecular Biology, Second Edition, Paul Singleton/Diana Sainsbury, pages 707 and 934 | | | | | |
| Examiner | | | | | | Date Considered | |
| *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--|-----|---|--|--|--|------------------------------|--|
| Form PTO 1449 (Modified) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO. 284024US0PCT | | SERIAL NO. 10/566,101 | |
| LIST OF REFERENCES CITED BY APPLICANT | | | | APPLICANT Ramon MERCE VIDAL, et al. | | | |
| | | | | FILING DATE August 10, 2006 | | GROUP 1625 | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | DAA | J.C. BENTLEY, et al., J. Psychopharmacol., page A64, Abstract No. 255 (1997) | | | | | |
| | DAB | J.C. BENTLEY, et al., British Journal of Pharmacology, Vol. 126, pp. 1537-1542 (1999) | | | | | |
| | DAC | J. SVARTENGREN, et al., Int. J. Obes, page 566, Abstract No. T1:P1-094 (2003) | | | | | |
| | DAD | | | | | | |
| | DAE | | | | | | |
| | DAF | | | | | | |
| | DAG | | | | | | |
| | DAH | | | | | | |
| | DAI | | | | | | |
| | DAJ | | | | | | |
| | DAK | | | | | | |
| | DAL | | | | | | |
| | DAM | | | | | | |
| | DAN | | | | | | |
| | DAO | | | | | | |
| | DAP | | | | | | |
| | DAQ | | | | | | |
| Examiner | | | | | | Date Considered | |
| *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |